In this issue:
Bevacizumab + FOLFOXIRI for initially unresectable colorectal liver metastases
Predicting long-term survival with chemo + bevacizumab in mCRC
Adding bevacizumab to standard first-line chemo: PFS benefit?
Single-agent bevacizumab has little value in mCRC
Panitumumab in mCRC: RAS mutations matter
Bevacizumab effective in second-line mCRC
Ramucirumab improves survival in second-line mCRC
Cetuximab + first-line FOLFIRI benefits RAS WT tumours
Adjuvant oxaliplatin: survival benefit in >70 years
Early vs late adjuvant chemotherapy in CRC . . . how does it impact upon survival?
Please login below to download this issue (PDF)